CoChat

A therapeutic role for cyclooxygenase‐2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis

Pompl, P. N., Ho, L., Bianchi, M., McManus, T., Qin, W., Pasinetti, G. M. · 2003 · The FASEB Journal
Cited by 144

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Recent studies indicate that the proinflammatory enzyme cyclooxygenase (COX)‐2, an enzyme involved in inflammatory cascades but also normal neuronal activities, is elevated in the brain and spinal cord of amyotrophic lateral sclerosis (ALS) patients and ALS mouse model systems. On the basis of this evidence, we explored the impact of COX‐2 inhibition on the onset and progression of ALS‐like disease in the G93A human superoxide dismutase (SOD)1 mouse model of ALS. We found that prophylactic administration of nimesulide, a preferential COX‐2 inhibitor, in the feed resulted in a significant delay in the onset of ALS type motor impairment. This delay of ALS symptomatology temporally overlapped with the inhibition of prostaglandin E 2 elevation in the spinal cord of SOD1‐G93A transgenic mice relative to untreated SOD1‐G93A controls. This study strongly supports a role for COX‐2 in the pathophysiology of ALS and provides the first experimental evidence that prophylactic treatment with COX‐2 inhibitors can significantly delay the onset of motor dysfunction in the SOD1‐G93A transgenic mouse model of ALS.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1096/fj.02-0876fje

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

Metadata

Authors
Pompl, P. N., Ho, L., Bianchi, M., McManus, T., Qin, W., & Pasinetti, G. M.
Venue
The FASEB Journal
Publisher
Wiley
Published
2003-02-05
Volume
17
Issue
6
Pages
725-727
ISSN
  • 0892-6638 (ISSN-L)
  • 1530-6860
OpenAlex
W2115637560
Cited by
144
References
2
FWCI
10.15
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.